Clinical Trial Update: Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID) [Phase 4]

View source ↗

Summary

Phase 4 trial assessing safety and tolerability of higher infusion parameters of Hizentra (IgPro20) in patients with primary immunodeficiency.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency

Drugs mentioned

• Hizentra (subcutaneous immunoglobulin (IgG))

Snippet

Sponsor: CSL Behring | Conditions: Primary Immunodeficiency | Phase 4 | Status: COMPLETED | Results posted: 2020-01-13